Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Nino G;Nino G; Hu A; Grunstein JS; Grunstein MM
  • Source:
    American journal of physiology. Lung cellular and molecular physiology [Am J Physiol Lung Cell Mol Physiol] 2009 Oct; Vol. 297 (4), pp. L746-57. Date of Electronic Publication: 2009 Aug 07.
  • Publication Type:
    Journal Article; Research Support, N.I.H., Extramural
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: American Physiological Society Country of Publication: United States NLM ID: 100901229 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-1504 (Electronic) Linking ISSN: 10400605 NLM ISO Abbreviation: Am J Physiol Lung Cell Mol Physiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Bethesda, MD : American Physiological Society, c1989-
    • Subject Terms:
      Desensitization, Immunologic*; Asthma/*metabolism ; Muscle, Smooth, Vascular/*immunology ; Muscle, Smooth, Vascular/*metabolism ; Receptors, Adrenergic, beta-2/*metabolism ; Respiratory System/*immunology ; Respiratory System/*metabolism; Adrenergic beta-2 Receptor Agonists ; Animals ; Asthma/immunology ; Asthma/pathology ; Blotting, Western ; Cells, Cultured ; Cyclic AMP/pharmacology ; Cyclic AMP Response Element-Binding Protein/metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 3 ; Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism ; Humans ; Mitogen-Activated Protein Kinase 1/metabolism ; Mitogen-Activated Protein Kinase 3/metabolism ; Muscle Contraction/drug effects ; Muscle Relaxation/drug effects ; Muscle, Smooth, Vascular/drug effects ; Phosphoric Diester Hydrolases/genetics ; Phosphoric Diester Hydrolases/metabolism ; Phosphorylation/drug effects ; Proteins/metabolism ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Rabbits ; Respiratory System/drug effects ; Reverse Transcriptase Polymerase Chain Reaction ; Signal Transduction
    • Abstract:
      Use of long-acting beta(2)-adrenergic receptor (beta2AR) agonists to treat asthma incurs an increased risk of asthma morbidity with impaired bronchodilation and heightened bronchoconstriction, reflecting the adverse effects of prolonged homologous beta2AR desensitization on airway smooth muscle (ASM) function. Since phosphodiesterase 4 (PDE4) regulates ASM relaxation and contractility, we examined whether the changes in ASM function induced by prolonged homologous beta2AR desensitization are attributed to altered expression and action of PDE4. Cultured human ASM cells and isolated rabbit ASM tissues exposed for 24 h to the long-acting beta2AR agonist salmeterol exhibited impaired acute beta2AR-mediated cAMP accumulation and relaxation, respectively, together with ASM constrictor hyperresponsiveness. These proasthmatic-like changes in ASM function were associated with upregulated PDE4 activity due to enhanced expression of the PDE4D5 isoform and were prevented by pretreating the ASM preparations with the PDE4 inhibitor rolipram or with inhibitors of either PKA or ERK1/2 signaling. Extended studies using gene silencing and pharmacological approaches demonstrated that: 1) the mechanism underlying upregulated PDE4D5 expression following prolonged beta2AR agonist exposure involves PKA-dependent activation of G(i) protein signaling via its betagamma-subunits, which elicits downstream activation of ERK1/2 and its induction of PDE4D5 transcription; and 2) the induction of PDE4 activity and consequent changes in ASM responsiveness are prevented by pretreating the beta2AR agonist-exposed ASM preparations with inhibitors of G(i)-betagamma signaling. Collectively, these findings identify that the proasthmatic changes in ASM function resulting from prolonged homologous beta2AR desensitization are attributed to upregulated PDE4 expression induced by G(i)-betagamma-mediated cross-talk between the PKA and ERK1/2 signaling pathways.
    • References:
      EMBO J. 2006 May 17;25(10):2051-61. (PMID: 16642035)
      Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):449-55. (PMID: 16293792)
      N Engl J Med. 1992 Oct 22;327(17):1198-203. (PMID: 1357550)
      Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6751-6. (PMID: 10841571)
      Mol Pharmacol. 2002 Nov;62(5):971-4. (PMID: 12391258)
      J Biol Chem. 2007 Nov 23;282(47):34235-49. (PMID: 17855344)
      Respir Med. 2001 Aug;95 Suppl B:S7-11. (PMID: 11534896)
      Am J Physiol. 1995 Nov;269(5 Pt 1):L645-52. (PMID: 7491984)
      Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):988-91. (PMID: 9310023)
      Life Sci. 2006 Oct 26;79(22):2077-85. (PMID: 16875702)
      Can Respir J. 2001 Sep-Oct;8(5):349-55. (PMID: 11694915)
      Biochem J. 2003 Feb 15;370(Pt 1):1-18. (PMID: 12444918)
      Eur Respir J. 2006 Jun;27(6):1286-306. (PMID: 16772391)
      J Biol Chem. 2002 Sep 27;277(39):35980-9. (PMID: 12121997)
      Am J Respir Cell Mol Biol. 1998 Aug;19(2):338-48. (PMID: 9698608)
      Drug Saf. 1997 May;16(5):295-308. (PMID: 9187530)
      Respir Physiol Neurobiol. 2003 Sep 16;137(2-3):179-95. (PMID: 14516725)
      J Allergy Clin Immunol. 1999 Aug;104(2 Pt 2):S18-30. (PMID: 10452785)
      Am J Respir Crit Care Med. 2005 Apr 15;171(8):823-8. (PMID: 15665325)
      J Allergy Clin Immunol. 2005 Aug;116(2):292-8. (PMID: 16083782)
      J Biol Chem. 1994 Feb 25;269(8):6193-7. (PMID: 8119963)
      J Biol Chem. 2000 Aug 25;275(34):26615-24. (PMID: 10851231)
      Eur J Pharmacol. 2007 Oct 1;571(2-3):215-21. (PMID: 17610865)
      Nature. 1997 Nov 6;390(6655):88-91. (PMID: 9363896)
      Am J Respir Cell Mol Biol. 2008 Jan;38(1):1-7. (PMID: 17673687)
      J Biol Chem. 2003 Feb 21;278(8):5493-6. (PMID: 12493749)
      Eur Respir J. 1997 Feb;10(2):330-6. (PMID: 9042628)
      Am J Respir Crit Care Med. 2001 Jan;163(1):173-84. (PMID: 11208644)
      J Biol Chem. 1994 Mar 18;269(11):7851-4. (PMID: 8132501)
      Eur J Pharmacol. 1995 Apr 28;289(2):235-47. (PMID: 7621897)
      Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1055-67. (PMID: 18359889)
      Biochemistry. 2005 Oct 25;44(42):13771-82. (PMID: 16229467)
      Chest. 2006 Jan;129(1):15-26. (PMID: 16424409)
      Nature. 1994 Jun 2;369(6479):418-20. (PMID: 8196770)
      J Biol Chem. 1995 Oct 6;270(40):23598-604. (PMID: 7559525)
      J Allergy Clin Immunol. 2005 Jul;116(1):94-101. (PMID: 15990780)
      FASEB J. 2003 Oct;17(13):1831-41. (PMID: 14519662)
      Mol Immunol. 2007 Mar;44(7):1729-36. (PMID: 17045653)
      Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12706-10. (PMID: 7809106)
    • Grant Information:
      HL-31467 United States HL NHLBI NIH HHS; HL-61038 United States HL NHLBI NIH HHS
    • Accession Number:
      0 (Adrenergic beta-2 Receptor Agonists)
      0 (Cyclic AMP Response Element-Binding Protein)
      0 (Proteins)
      0 (RNA, Messenger)
      0 (Receptors, Adrenergic, beta-2)
      E0399OZS9N (Cyclic AMP)
      EC 2.3.1.84 (alcohol O-acetyltransferase)
      EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
      EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
      EC 3.1.4.- (Phosphoric Diester Hydrolases)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 3)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4)
      EC 3.1.4.17 (PDE4D protein, human)
    • Publication Date:
      Date Created: 20090812 Date Completed: 20091105 Latest Revision: 20211020
    • Publication Date:
      20231215
    • Accession Number:
      PMC2770790
    • Accession Number:
      10.1152/ajplung.00079.2009
    • Accession Number:
      19666775